Review
Immunology
Ying Wang, Pengfei Huo, Rulin Dai, Xin Lv, Shaofei Yuan, Yang Zhang, Yiming Guo, Rui Li, Qian Yu, Kun Zhu
Summary: The effectiveness of convalescent plasma (CP) immunotherapy for COVID-19 in reducing mortality and improving clinical symptoms remains controversial based on current evidence, but it may have a positive impact on treating COVID-19 patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Immunology
Fethi Gul, Zeynep Burcin Gonen, Olcay Y. Jones, Neslihan Pakize Tasli, Gokmen Zararsiz, Ekrem Unal, Aykut Ozdarendeli, Fikrettin Sahin, Ahmet Eken, Semih Yilmaz, Musa Karakukcu, Oguz Kaan Kirbas, Nur Seda Gokdemir, Batuhan Turhan Bozkurt, Yusuf Ozkul, Burcin Doruk Oktay, Muhammet Ali Uygut, Ismail Cinel, Mustafa Cetin
Summary: This is a single-center prospective study that investigated the safety and efficacy of ChipEXO(TM) for severe COVID-19 pneumonia. The results showed that aerosolized ChipEXO(TM) treatment was effective in improving oxygenation parameters and reducing disease activity scores and inflammatory markers.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Virology
Ali S. Omrani, Ahmed Zaqout, Anas Baiou, Joanne Daghfal, Naser Elkum, Rand A. Alattar, Dana Bakdach, Hatem Abusriwil, Abdalrahman M. Mostafa, Bassem Alhariri, Naseem Ambra, Mohamed Khatib, Ali M. Eldeeb, Zeyd Merenkov, Zeinab Fawzi, Saloua M. Hmissi, Ali A. Hssain, Peter V. Coyle, Hussam Alsoub, Muna A. Almaslamani, Abdullatif Alkhal
Summary: A study compared critically ill COVID-19 patients who received standard care with those who also received convalescent plasma therapy, finding no clinical benefits associated with convalescent plasma. There were no significant differences in 28-day mortality rates and viral clearance rates between the two groups, and randomized trials are needed to confirm these findings.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Review
Immunology
Anselm Jorda, Manuel Kussmann, Nebu Kolenchery, Jolanta M. Siller-Matula, Markus Zeitlinger, Bernd Jilma, Georg Gelbenegger
Summary: The efficacy of convalescent plasma treatment for Covid-19 remains uncertain. A systematic review and meta-analysis of randomized controlled trials found that treatment with convalescent plasma did not result in lower all-cause mortality or improved disease progression in patients with Covid-19, regardless of disease severity and baseline antibody status.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Sitaram Khadka, Shameem Nisar, Nawazish-i-Husain Syed, Dhan Bahadur Shrestha, Pravash Budhathoki
Summary: The COVID-19 pandemic is posing a serious threat to global survival, severely impacting governments and healthcare systems worldwide. Existing therapies are uncertain and require further clinical trials to establish efficacy and safety.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
(2021)
Article
Medicine, General & Internal
D. J. Sullivan, K. A. Gebo, S. Shoham, E. M. Bloch, B. Lau, A. G. Shenoy, G. S. Mosnaim, T. J. Gniadek, Y. Fukuta, B. Patel, S. L. Heath, A. C. Levine, B. R. Meisenberg, E. S. Spivak, S. Anjan, M. A. Huaman, J. E. Blair, J. S. Currier, J. H. Paxton, J. M. Gerber, J. R. Petrini, P. B. Broderick, W. Rausch, M-E Cordisco, J. Hammel, B. Greenblatt, V. C. Cluzet, D. Cruser, K. Oei, M. Abinante, L. L. Hammitt, C. G. Sutcliffe, D. N. Forthal, M. S. Zand, E. R. Cachay, J. S. Raval, S. G. Kassaye, E. C. Foster, M. Roth, C. E. Marshall, A. Yarava, K. Lane, N. A. McBee, A. L. Gawad, N. Karlen, A. Singh, D. E. Ford, D. A. Jabs, L. J. Appel, D. M. Shade, S. Ehrhardt, S. N. Baksh, O. Laeyendecker, A. Pekosz, S. L. Klein, A. Casadevall, A. A. R. Tobian, D. F. Hanley
Summary: This study evaluated the efficacy and safety of COVID-19 convalescent plasma in symptomatic adults and found that receiving convalescent plasma transfusion reduced the risk of hospitalization due to COVID-19-related reasons.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Medicine, General & Internal
Alejandro Piscoya, Luis F. Ng-Sueng, Angela Parra del Riego, Renato Cerna-Viacava, Vinay Pasupuleti, Priyaleela Thota, Yuani M. Roman, Adrian V. Hernandez
Summary: Convalescent plasma did not reduce all-cause mortality in hospitalized COVID-19 patients compared to standard of care or placebo + standard of care in randomized controlled trials. There was no significant effect of convalescent plasma on other clinical outcomes or safety outcomes. Low quality evidence suggests that convalescent plasma may not be recommended for hospitalized COVID-19 patients.
ARCHIVES OF MEDICAL SCIENCE
(2021)
Review
Pharmacology & Pharmacy
T. M. Yunus Khan, I. A. Badruddin, S. A. Saquib, R. Mohamed, S. Arora, M. A. K. Mohammed, S. V. Shamsuddin, S. Khateeb, A. A. Khan, V. Grover, Priyanka Saluja
Summary: This article provides an up-to-date review of the use of convalescent plasma therapy as a treatment option for coronavirus disease 2019, exploring its safety, efficacy, and potential challenges.
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2022)
Review
Infectious Diseases
Behnaz Esmaeili, Shahnaz Esmaeili, Zahra Pourpak
Summary: Most studies suggest that CP infusion is safe and can improve clinical outcomes and reduce viral load in patients. Further investigation is needed to understand the impact of CP infusion on adaptive immune response and inflammatory factors in patients with coronavirus.
BMC INFECTIOUS DISEASES
(2021)
Article
Virology
Laura Thuemmler, Monika Lindemann, Peter A. Horn, Veronika Lenz, Margarethe Konik, Anja Gaeckler, Kristina Boss, Fotis Theodoropoulos, Vasiliki Besa, Christian Taube, Thorsten Brenner, Oliver Witzke, Adalbert Krawczyk, Hana Rohn
Summary: Vulnerable patients such as immunosuppressed or elderly patients are at high risk for severe COVID-19 and can be effectively protected by immunotherapy with SARS-CoV-2 specific monoclonal antibodies (mAb) or convalescent plasma. Our study showed that mAb treatment is highly effective in preventing severe courses of SARS-CoV-2 infection, while convalescent plasma treatment improved overall survival of high-risk COVID-19 patients.
Article
Immunology
Penelope-Georgia Papayanni, Dimitrios Chasiotis, Kiriakos Koukoulias, Aphrodite Georgakopoulou, Anastasia Iatrou, Eleni Gavriilaki, Chrysavgi Giannaki, Militsa Bitzani, Eleni Geka, Polychronis Tasioudis, Diamantis Chloros, Asimina Fylaktou, Ioannis Kioumis, Maria Triantafyllidou, Sotiria Dimou-Besikli, Georgios Karavalakis, Afroditi K. Boutou, Eleni Siotou, Achilles Anagnostopoulos, Anastasia Papadopoulou, Evangelia Yannaki
Summary: The study demonstrates a causal relationship between the expansion of SARS-CoV-2-specific T cells and disease outcome in COVID-19 patients, with insufficient expansion correlating with adverse outcomes in hospitalized patients. T cells generated from convalescent and vaccinated donors showed functional activity against multiple virus variants, while cells from critical patients failed to expand, mirroring the in vivo failure of specific T-cell immunity in controlling infection.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Khalid Shrwani, Ravi Sharma, Madhan Krishnan, Terry Jones, Martin Mayora-Neto, Diego Cantoni, Nigel J. Temperton, Susan L. Dobson, Krishanthi Subramaniam, Paul S. McNamara, Nigel A. Cunliffe, Lance Turtle, Qibo Zhang
Summary: The study showed that cross-reactive anti-SARS-CoV-2 antibodies were present in prepandemic serum samples from children and young adults, which may derive from immunological memory to common HCoVs. This cross-reactive immune and memory response could be an effective strategy against SARS-CoV-2 and future novel coronaviruses.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Medicine, General & Internal
Claire Iannizzi, Khai Li Chai, Vanessa Piechotta, Sarah J. Valk, Catherine Kimber, Ina Monsef, Erica M. Wood, Abigail A. Lamikanra, David J. Roberts, Zoe McQuilten, Cynthia So-Osman, Aikaj Jindal, Nora Cryns, Lise J. Estcourt, Nina Kreuzberger, Nicole Skoetz
Summary: This study investigated the effectiveness and safety of convalescent plasma transfusion for COVID-19 patients. The results showed that convalescent plasma had limited impact on reducing mortality, improving clinical status, reducing the need for mechanical ventilation, and increasing discharge rates. Compared to placebo or standard care, convalescent plasma did not show significant advantages in patient outcomes.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2023)
Article
Immunology
Gil C. De Santis, Luciana Correa Oliveira, Pedro M. M. Garibaldi, Carlos E. L. Almado, Julio Croda, Ghislaine G. A. Arcanjo, Erika A. F. Oliveira, Adriana C. Tonacio, Dante M. Langhi Jr, Jose O. Bordin, Renato N. Gilio, Leonardo C. Palma, Elaine Santos, Simone K. Haddad, Benedito P. A. Prado Jr, Marjorie Cornejo Pontelli, Rogerio Gomes, Carlos H. Miranda, Maria Auxiliadora Martins, Dimas T. Covas, Eurico Arruda, Benedito A. L. Fonseca, Rodrigo T. Calado
Summary: A multicenter randomized trial in Brazil showed that high-dose convalescent plasma transfusion within 10 days of symptom onset did not benefit patients with severe COVID-19.
EMERGING INFECTIOUS DISEASES
(2022)
Review
Medicine, General & Internal
Vanessa Piechotta, Claire Iannizzi, Khai Li Chai, Sarah J. Valk, Catherine Kimber, Elena Dorando, Ina Monsef, Erica M. Wood, Abigail A. Lamikanra, David J. Roberts, Zoe McQuilten, Cynthia So-Osman, Lise J. Estcourt, Nicole Skoetz
Summary: Convalescent plasma and hyperimmune immunoglobulin are being investigated as potential therapies for COVID-19, with a living systematic review approach being used to assess their effectiveness and safety. The current evidence suggests that convalescent plasma does not reduce all-cause mortality or significantly improve clinical outcomes for individuals with moderate to severe disease, but its impact on other outcomes remains uncertain. Further ongoing studies are needed to determine the full potential of these interventions.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
